Literature DB >> 12520711

Evolution of myelofibrosis in chronic idiopathic myelofibrosis as evidenced in sequential bone marrow biopsy specimens.

Thomas Buhr1, Guntram Büsche, Harald Choritz, Florian Länger, Hans Kreipe.   

Abstract

Although the new World Health Organization (WHO) classification acknowledges "prefibrotic" phases, progression of myelofibrosis in chronic idiopathic myelofibrosis (cIMF) is controversial because there are only a few studies about sequential biopsy specimens, and they yield conflicting results. The conflicting results might be due to a mixture of different degrees of myelofibrosis and therapy regimens within the respective groups studied. To prove this hypothesis, we studied sequential bone marrow biopsy specimens from patients with cIMF and compared 3 groups with different degrees of myelofibrosis at initial diagnosis with a group of patients with primarily unfibrosed disease who met the WHO criteria for prefibrotic cIMF. Patients receiving chemotherapy were considered separately from patients without treatment. Our results favor a steady progression of myelofibrosis unrelated to therapy modalities, whereas confusing literature data can be explained: fibrosis may remain static or lessen, especially in more advanced stages of cIMF.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12520711     DOI: 10.1309/PTVG-B3DX-B8A8-M7KD

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  12 in total

1.  European Bone Marrow Working Group trial on reproducibility of World Health Organization criteria to discriminate essential thrombocythemia from prefibrotic primary myelofibrosis. Haematologica 2012;97(3):360-5--comment.

Authors:  Jürgen Thiele; Attilio Orazi; Hans Michael Kvasnicka; Vito Franco; Emanuela Boveri; Umberto Gianelli; Heinz Gisslinger; Francesco Passamonti; Ayalew Tefferi; Tiziano Barbui
Journal:  Haematologica       Date:  2012-03       Impact factor: 9.941

2.  Aberrant collagenase expression in chronic idiopathic myelofibrosis is related to the stage of disease but not to the JAK2 mutation status.

Authors:  Oliver Bock; Johanne Neuse; Kais Hussein; Kai Brakensiek; Guntram Buesche; Thomas Buhr; Birgitt Wiese; Hans Kreipe
Journal:  Am J Pathol       Date:  2006-08       Impact factor: 4.307

3.  The clinical importance of moderate/severe bone marrow fibrosis in patients with therapy-related myelodysplastic syndromes.

Authors:  Bin Fu; Chi Young Ok; Maitrayee Goswami; Wei Xei; Jesse M Jaso; Tariq Muzzafar; Carlos Bueso-Ramos; Srdan Verstovsek; Guillermo Garcia-Manero; L Jeffrey Medeiros; Sa A Wang
Journal:  Ann Hematol       Date:  2013-05-10       Impact factor: 3.673

4.  Detection of the single hotspot mutation in the JH2 pseudokinase domain of Janus kinase 2 in bone marrow trephine biopsies derived from chronic myeloproliferative disorders.

Authors:  Oliver Bock; Guntram Büsche; Christina Koop; Sabine Schröter; Thomas Buhr; Hans Kreipe
Journal:  J Mol Diagn       Date:  2006-05       Impact factor: 5.568

5.  The 2008 WHO diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis.

Authors:  Juergen Thiele; Hans Michael Kvasnicka
Journal:  Curr Hematol Malig Rep       Date:  2009-01       Impact factor: 3.952

6.  Bone morphogenetic proteins are overexpressed in the bone marrow of primary myelofibrosis and are apparently induced by fibrogenic cytokines.

Authors:  Oliver Bock; Julia Höftmann; Katharina Theophile; Kais Hussein; Birgitt Wiese; Jerome Schlué; Hans Kreipe
Journal:  Am J Pathol       Date:  2008-03-18       Impact factor: 4.307

7.  The allele burden of JAK2 V617F can aid in differential diagnosis of Philadelphia Chromosome-Negative Myeloproliferative Neoplasm.

Authors:  Sang Hyuk Park; Hyun-Sook Chi; Young-Uk Cho; Seongsoo Jang; Chan-Jeoung Park
Journal:  Blood Res       Date:  2013-06-25

8.  Coexistence of plasma cell dyscrasia with prefibrotic stage of primary myelofibrosis: a case report.

Authors:  George Tsirakis; Peggy Kanellou; Maria Kaparou; Andrew Passam; Amalia Zampoulaki; Kostas Stylianou; Michael G Alexandrakis
Journal:  ISRN Hematol       Date:  2011-05-19

9.  Effect of treatment with a JAK2-selective inhibitor, fedratinib, on bone marrow fibrosis in patients with myelofibrosis.

Authors:  Catriona Jamieson; Robert Hasserjian; Jason Gotlib; Jorge Cortes; Richard Stone; Moshe Talpaz; Jürgen Thiele; Scott Rodig; Olga Pozdnyakova
Journal:  J Transl Med       Date:  2015-09-10       Impact factor: 5.531

Review 10.  Rationale for revision and proposed changes of the WHO diagnostic criteria for polycythemia vera, essential thrombocythemia and primary myelofibrosis.

Authors:  T Barbui; J Thiele; A M Vannucchi; A Tefferi
Journal:  Blood Cancer J       Date:  2015-08-14       Impact factor: 11.037

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.